semaglutide and ckd FLOW Trial a kidney outcomes trial with once-weekly in people with type 2 diabetes chronic kidney disease Sema 1.0mg once weekly in CKD+T2D ✓ ↓ Composite kidney events ✓ Slower Semaglutide in Diabetic Kidney Disease:

People in the last stage of long-term, serious kidney disease need to undergo hemodialysis, which can lower L-carnitine levels

GLP-1 receptor agonists may be considered when additional treatment goals include weight reduction, improved glycemic control, chronic kidney disease risk reduction, or lowering atherosclerotic cardiovascular risk, particularly in patients with obesity or established Atherosclerotic Cardiovascular Disease (ASCVD) [7, 16, 47]

Besides curbing appetite, Semaglutide GLP-1 also decelerates gastric emptying, contributing to a prolonged sensation of fullness after eating

Inject SLOWLY Down the Vial Wall Critical: Angle the needle so it touches the inside glass wall

4.9%), compared with the placebo group

Commercial Insurance Coverage Rates A 2023 KFF analysis found that approximately 43% of large employer health plans covered at least one GLP-1 medication for obesity (not just diabetes) [17]